Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

Redx Pharma plc. (3/30/17). "Press Release: Redx Pharma Awarded US$1 Million Grant by CARB-X".

Organisations Organisation Redx Pharma plc (AIM: REDX)
  Group Redx Pharma (Group)
  Organisation 2 CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator)
Products Product antibiotic
  Product 2 drug development
Index term Index term Redx Pharma–CARB-X: grant, 201703– grant $1m over 18 months to advance candidates for drug resistant Gram-negative bacteria
Person Person Murray, Neil (Redx Pharma 201112 CEO)
     


> Redx selected as one of 11 initial candidates after competitive global selection process in recognition of innovative science programs

> Collaborative grant in anti-infectives enables Redx to advance its Gram-negative program with a prospective partner


Redx Pharma is pleased to announce that it has been awarded a US$1 million grant by CARB-X, one of the world’s largest public-private partnerships, launched in July 2016 to accelerate global antibacterial innovation and research. The 11 successful projects were selected through a competitive process from 168 applications from around the world. The awarded grants were based on the merits of each of the company’s research proposals, as evaluated by the CARB-X Advisory Board and the CARB-X team.

Today’s announcement by CARB-X showcases the first projects selected for the Powered by CARB-X portfolio, spotlighting Redx as a highly-respected partner of choice on a global stage. Redx will receive US$1 million over 18 months, with an option for future tiered milestone payments, to drive scientific progress against globally challenging drug resistant Gram-negative bacteria. This collaboration with CARB-X enables Redx to move its Gram-negative program into the next stage of development with a prospective partner.

Dr Neil Murray, Chief Executive Officer of Redx Pharma, said: "We are delighted to be collaborating with CARB-X, a truly innovative initiative that is targeting the development of new life-saving antibacterials and diagnostics. Receiving this grant today is testament to the great science that exists at Redx. This grant cements a path forward for our recently announced strategy, to secure external partners to ensure that our high quality anti-infective science will continue whilst we sharpen our focus on the clinical development of our oncology and immunology programs."

   
Record changed: 2017-05-27

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Redx Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px